Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of MEN-1309 in combination with Balstilimab in patients with solid tumors including lung, gastric and ovarian cancer

Next Previous
Search
Trial Profile

A clinical trial of MEN-1309 in combination with Balstilimab in patients with solid tumors including lung, gastric and ovarian cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 30 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Balstilimab (Primary) ; MEN 1309 (Primary)
  • Indications Gastric cancer; Lung cancer; Ovarian cancer; Solid tumours
  • Focus Therapeutic Use
  • Sponsors Oxford BioTherapeutics

    • Most Recent Events

    • 30 May 2022 New trial record
    • 25 May 2022 According to an Oxford BioTherapeutics (OBT) media release, has entered into a collaboration and supply agreement with Agenus Inc., to support this trial. Under the terms of the agreement, OBT will be the sponsor of the combination trial and responsible for operational execution, and Agenus will provide drug supply and scientific support.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top